3 completed, 1 active not recruiting, 1 recruiting. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Chondrosarcoma, Mesenchymal: new trials by email Literature Review of Chondrosarcoma, Mesenchymal trials Research Report on Chondrosarcoma, Mesenchymal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma Trabectedin - Mesenchymal Chondrosarcoma | Phase 2 | Recruiting | Italian Sarcoma Group | 16 | 2021-09-14 | 2026-03-27 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Regorafenib, Placebo - Liposarcoma, Osteogenic Sarcoma | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 131 | 2014-07-01 | 2023-11-07 |
| Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma sirolimus and cyclophosphamide - Conventional Chondrosarcoma, Myxoid Liposarcoma | Phase 2 | Completed | Leiden University Medical Center | 70 | 2014-06-01 | 2022-04-20 |
| Vismodegib in Treating Patients With Advanced Chondrosarcomas Laboratory Biomarker Analysis, Pharmacogenomic Study, Vismodegib - Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 45 | 2010-12-21 | 2026-08-13 |
Liposarcoma (2) · Chondrosarcoma (1) · Chondrosarcoma, Clear Cell (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Dermatofibrosarcoma (1) · Fibrosarcoma (1) · Granuloma, Plasma Cell (1) · Histiocytoma, Angiomatoid Fibrous (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Liposarcoma, Myxoid (1) · Nerve Sheath Neoplasms (1) · Neurofibrosarcoma (1) · Osteosarcoma (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Connective Tissue (5) · Neoplasms, Connective and Soft Tissue (5) · Chondrosarcoma (4) · Sarcoma (4) · Neoplasms, Adipose Tissue (3) · Neoplasms, Muscle Tissue (2) · Granuloma (1) · Histiocytoma (1) · Liposarcoma (1) · Myosarcoma (1) · Neoplasms, Bone Tissue (1) · Neoplasms, Fibrous Tissue (1) · Neoplasms, Nerve Tissue (1)
Cyclophosphamide (1) · Doxorubicin (1) · HhAntag691 (1) · Ifosfamide (1) · Pharmacogenomic Testing (1) · Radiation (1) · Radiotherapy (1) · Sirolimus (1) · Trabectedin (1) · pazopanib (1) · regorafenib (1)
National Cancer Institute (NCI) (2) · Italian Sarcoma Group (1) · Leiden University Medical Center (1) · Sarcoma Alliance for Research through Collaboration (1)
United States (2) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · Puerto Rico (1) · Spain (1)
Aaron R Weiss (1) · Antoine Italiano (1) · Hans Gelderblom, Prof (1) · Robert Maki, MD, PhD (1) · Silvia Stacchiotti, MD (1)
PMID 24170610, PMID 31013172, PMID 31401903, PMID 32701199, PMID 32702309, PMID 32827353, PMID 34515544, PMID 37523624
U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)